Kevin Quon
Insider ownership, small-cap, long-term horizon, dividend investing

Is Now The Time To Buy Ironwood Pharmaceuticals?

Pharmaceutical companies with recently commercialized products can often be promising investment opportunities. One such company that has recently launched a new treatment option is Ironwood Pharmaceuticals (IRWD). Ironwood Pharmaceuticals is a developing company looking to lead in the field of gastrointestinal therapeutics. The company is expanding the scientific frontier due to its pharmacologic expertise in guanylate cyclate pathways. The company is looking to introduce a new class of gastrointestinal medicines called GC-C agonists.

Ironwood's two most advanced GC-C agonists include "Linaclotide" and "IW-9179". In August 2012, Linaclotide gained approval from the U.S. Food and Drug Administration, allowing it to be sold under the trade name of Linzess. IW-9179 is a GC-C agonist designed to target upper...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details